BRCA1 Function in Post-Damage Nuclear Foci
BRCA1 Function in Post-Damage Nuclear Foci
批准号:
8080170
负责人:
DAVID Morse LIVINGSTON
金额:
$51.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2014-05-31
关键词:
BRCA1 geneBindingBinding ProteinsBiochemicalBreastCell NucleusComplexDNA Double Strand BreakDevelopmentDiseaseDouble Strand Break RepairEventGenerationsGenomeInheritedIonizing radiationLearningLocationMalignant NeoplasmsMalignant neoplasm of ovaryMutateMutationNuclearNuclear ProteinNuclear StructureOncogenesPolyubiquitinProcessProteinsRiskSeriesSiteStructureTimeTumor SuppressionTumor Suppressor GenesWomanY proteincancer cellclinically relevantexperiencehomologous recombinationin vivoinsightmalignant breast neoplasmpublic health relevancerepairedresponsetumorubiquitin-protein ligase
中文摘要
描述(申请人提供):BRCA 1是一种肿瘤抑制基因产物,专门用于抑制乳腺癌和卵巢癌的发展。它编码一个1863个残基的核蛋白,p220。p220对多种形式的基因组完整性控制做出贡献,其中之一是通过同源重组(HR)支持双链DNA断裂(DSB)修复的能力。许多间接证据表明,p220支持HR的能力与其肿瘤抑制功能之间存在很强的相关性,但这两者在生物化学上是如何联系的尚不清楚。更具体地说,p220必须执行什么样的体内生化功能才能发挥其肿瘤抑制功能,以及这两组功能如何相互联系,也是未知的。在这方面,在DSB产生后(例如通过电离辐射),p220被迅速吸引到这些受损部位,一段时间后,集中在这些位置形成的局灶性核结构(也称为电离辐射诱导的病灶=IRIF)中。p220一旦集中在IRIF中执行什么功能,以及它们如何有助于肿瘤抑制也是未知的。最近,我们和其他人检测到一系列特定的生化步骤,使p220获得IRIF。它们涉及核多聚泛素结合蛋白Rap 80及其相关的去泛素化酶BRCC 36和Abraxas的活性,Abraxas是一种在p220和Rap 80之间起桥梁作用的核蛋白。所有人都在IRIF中浓缩并参与共浓缩p220。这项建议旨在:a)破译将Rap 80拴系到IRIF的特定生物化学事件; B)理解与IRIF中p220浓度相关的功能意义;和c)了解这些事件以何种方式与p220癌症抑制功能的执行相关。BRCA 1是一种乳腺癌和卵巢癌基因。当它以突变状态遗传时,女性患上这两种疾病之一或两者的风险比正常情况高得多。该提案旨在了解BRCA 1如何在细胞核内发挥作用,以及为什么当其功能因突变而出现缺陷时,癌细胞会发展。
英文摘要
DESCRIPTION (provided by applicant): BRCA1 is a tumor suppressor gene product dedicated to the suppression of breast and ovarian cancer development. It encodes an 1863 residue nuclear protein, p220. p220 makes contributions to multiple forms of genome integrity control, among which is an ability to support the repair of double strand DNA breaks (DSB) by homologous recombination (HR). Much circumstantial evidence suggests a strong correlation between the ability of p220 to support HR and to perform its tumor suppression function, but how the two are connected, biochemically, is unknown. More specifically, what in vivo biochemical functions p220 must execute to perform its tumor suppressing function and how the two sets of functions are connected to one another are also unknown. In this regard, after the generation of DSBs (e.g. by ionizing radiation), p220 is rapidly attracted to these damaged sites and, some time later, concentrates in focal nuclear structures (aka Ionizing Radiation Induced Foci=IRIF) that form at these locations. What functions p220 performs, once concentrated in IRIF, and how, as is suspected, they contribute to tumor suppression are also unknown. Recently, we and others detected a series of specific biochemical steps that allow p220 to gain access to IRIF. They involve the activities of a nuclear, polyubiquitin-binding protein, Rap80, its associated deubiquitinase, BRCC36, and Abraxas, a nuclear protein that serves as a bridge between p220 and Rap80. All concentrate in IRIF and participate in co-concentrating p220. This proposal is aimed at: a) deciphering the specific biochemical events that tether Rap80 to IRIF; b) at understanding the functional significance associated with p220 concentration in IRIF; and c) learning in what ways these events relate to the execution of p220 cancer suppression function. PUBLIC HEALTH RELEVANCE: BRCA1 is a breast and ovarian cancer gene. When it is inherited in a mutated state, women experience a much higher than normal risk of developing one or both of these diseases. This proposal is aimed at understanding how BRCA1 functions inside the nucleus of cells and why, when its function is rendered defective by mutation, cancer cells develop.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deciphering the mechanism underlying BRCA1 breast cancer development
-
批准号:10218120
-
项目类别:
-
资助金额:$105.34万
-
财政年份:2019
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Deciphering the mechanism underlying BRCA1 breast cancer development
-
批准号:9814452
-
项目类别:
-
资助金额:$84.51万
-
财政年份:2019
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 Function in Post-Damage Nuclear Foci
-
批准号:9454879
-
项目类别:
-
资助金额:$3.38万
-
财政年份:2017
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Viral Oncoprotein Inhibition of Quiescence
-
批准号:8233033
-
项目类别:
-
资助金额:$44.63万
-
财政年份:2011
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Administrative Core
-
批准号:8233035
-
项目类别:
-
资助金额:$4.04万
-
财政年份:2011
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA 1 and 2 and Breast Cancer Development
-
批准号:8215974
-
项目类别:
-
资助金额:$46.74万
-
财政年份:2011
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Viral Oncoprotein Inhibition of Quiescence
-
批准号:7647592
-
项目类别:
-
资助金额:$45.18万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 Function in Post-Damage Nuclear Foci
-
批准号:9196343
-
项目类别:
-
资助金额:$51.55万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 Function in Post-Damage Nuclear Foci
-
批准号:8465745
-
项目类别:
-
资助金额:$48.08万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Administrative Core
-
批准号:7647595
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 Function in Post-Damage Nuclear Foci
-
批准号:9027449
-
项目类别:
-
资助金额:$51.55万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Biology and treatment of Brca1-Associated and Sporadic Basal-Like cancers
-
批准号:7927063
-
项目类别:
-
资助金额:$13.26万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 Function in Post-Damage Nuclear Foci
-
批准号:8266522
-
项目类别:
-
资助金额:$51.16万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 Function in Post-Damage Nuclear Foci
-
批准号:7729519
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA 1 and 2 and Breast Cancer Development
-
批准号:7617418
-
项目类别:
-
资助金额:$48.71万
-
财政年份:2009
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
Biology and treatment of Brca1-Associated and Sporadic Basal-Like cancers
-
批准号:7729483
-
项目类别:
-
资助金额:$7.76万
-
财政年份:2008
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 and the Inactive X Chromosome
-
批准号:6696977
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2004
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 and the Inactive X Chromosome
-
批准号:6892151
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2004
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
SV40 T/t Interactions with Pocket Proteins
-
批准号:6989679
-
项目类别:
-
资助金额:$28.1万
-
财政年份:2004
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
BRCA1 and the Inactive X Chromosome
-
批准号:7192487
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2004
-
负责人:DAVID Morse LIVINGSTON
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: